🚀 VC round data is live in beta, check it out!
aTyr Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for aTyr Pharma and similar public comparables like BeyondSpring, Valerio Therapeutics, IBT, InflaRx and more.
aTyr Pharma Overview
About aTyr Pharma
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Founded
2005
HQ
Employees
59
Website
Sectors
Financials (LTM)
EV
$7M
aTyr Pharma Financials
aTyr Pharma reported last 12-month revenue of $138K and negative EBITDA of ($74M).
In the same LTM period, aTyr Pharma generated $69K in gross profit, ($74M) in EBITDA losses, and had net loss of ($69M).
Revenue (LTM)
aTyr Pharma P&L
In the most recent fiscal year, aTyr Pharma reported revenue of $190K and EBITDA of ($76M).
aTyr Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $138K | XXX | $190K | XXX | XXX | XXX |
| Gross Profit | $69K | XXX | — | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($74M) | XXX | ($76M) | XXX | XXX | XXX |
| EBITDA Margin | (53316%) | XXX | (40039%) | XXX | XXX | XXX |
| EBIT Margin | (52531%) | XXX | (40856%) | XXX | XXX | XXX |
| Net Profit | ($69M) | XXX | ($74M) | XXX | XXX | XXX |
| Net Margin | (50214%) | XXX | (39009%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
aTyr Pharma Stock Performance
aTyr Pharma has current market cap of $74M, and enterprise value of $7M.
Market Cap Evolution
aTyr Pharma's stock price is $0.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7M | $74M | -6.2% | XXX | XXX | XXX | $-0.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialaTyr Pharma Valuation Multiples
aTyr Pharma trades at 49.9x EV/Revenue multiple, and (0.1x) EV/EBITDA.
EV / Revenue (LTM)
aTyr Pharma Financial Valuation Multiples
As of April 11, 2026, aTyr Pharma has market cap of $74M and EV of $7M.
Equity research analysts estimate aTyr Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
aTyr Pharma has a P/E ratio of (1.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $74M | XXX | $74M | XXX | XXX | XXX |
| EV (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV/Revenue | 49.9x | XXX | 36.2x | XXX | XXX | XXX |
| EV/EBITDA | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.1x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 99.8x | XXX | — | XXX | XXX | XXX |
| P/E | (1.1x) | XXX | (1.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified aTyr Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
aTyr Pharma Margins & Growth Rates
aTyr Pharma's revenue in the last 12 month grew by 1645%.
aTyr Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
aTyr Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1645% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (53316%) | XXX | (40039%) | XXX | XXX | XXX |
| EBITDA Growth | (13%) | XXX | (16%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12599% | XXX | 9262% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 39860% | XXX | 31694% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40956% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
aTyr Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BeyondSpring | XXX | XXX | XXX | XXX | XXX | XXX |
| Valerio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| IBT | XXX | XXX | XXX | XXX | XXX | XXX |
| InflaRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Fractyl Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
aTyr Pharma M&A Activity
aTyr Pharma acquired XXX companies to date.
Last acquisition by aTyr Pharma was on XXXXXXXX, XXXXX. aTyr Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by aTyr Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialaTyr Pharma Investment Activity
aTyr Pharma invested in XXX companies to date.
aTyr Pharma made its latest investment on XXXXXXXX, XXXXX. aTyr Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by aTyr Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout aTyr Pharma
| When was aTyr Pharma founded? | aTyr Pharma was founded in 2005. |
| Where is aTyr Pharma headquartered? | aTyr Pharma is headquartered in United States. |
| How many employees does aTyr Pharma have? | As of today, aTyr Pharma has over 59 employees. |
| Who is the CEO of aTyr Pharma? | aTyr Pharma's CEO is Sanjay S. Shukla. |
| Is aTyr Pharma publicly listed? | Yes, aTyr Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of aTyr Pharma? | aTyr Pharma trades under ATYR ticker. |
| When did aTyr Pharma go public? | aTyr Pharma went public in 2015. |
| Who are competitors of aTyr Pharma? | aTyr Pharma main competitors are BeyondSpring, Valerio Therapeutics, IBT, InflaRx. |
| What is the current market cap of aTyr Pharma? | aTyr Pharma's current market cap is $74M. |
| What is the current revenue of aTyr Pharma? | aTyr Pharma's last 12 months revenue is $138K. |
| What is the current revenue growth of aTyr Pharma? | aTyr Pharma revenue growth (NTM/LTM) is 1645%. |
| What is the current EV/Revenue multiple of aTyr Pharma? | Current revenue multiple of aTyr Pharma is 49.9x. |
| Is aTyr Pharma profitable? | No, aTyr Pharma is not profitable. |
| What is the current EBITDA of aTyr Pharma? | aTyr Pharma has negative EBITDA and is not profitable. |
| What is aTyr Pharma's EBITDA margin? | aTyr Pharma's last 12 months EBITDA margin is (53316%). |
| What is the current EV/EBITDA multiple of aTyr Pharma? | Current EBITDA multiple of aTyr Pharma is (0.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.